Semaglutide and tirzepatide were associated with better hospitalization and mortality outcomes than sitagliptin in HFpEF and type 2 diabetes.

There are improved cardiovascular outcomes associated with semaglutide therapy in patients with overweight or obesity without diabetes.

Semaglutide improves heart failure-related symptoms and physical function and results in greater weight loss compared with placebo in patients with heart failure with preserved ejection fraction ...

ATLANTA — Weekly injections of the glucagon-like peptide (GLP-1) receptor agonist semaglutide (Wegovy, Ozempic), relieves symptoms in patients with heart failure with preserved ejection fraction ...

In the ever-evolving landscape of weight management and diabetes treatment, semaglutide has emerged as a significant player. Originally approved by the FDA for managing type 2 diabetes under Ozempic, ...

In a recent large-scale retrospective cohort study published in the journal Primary Care Diabetes, researchers used a comprehensive (n = 10,465) database-derived dataset to evaluate the adherence and ...

Delaware-Based Telehealth Platform Reports Increased Patient Interest in Cash-Pay Compounded Semaglutide and Tirzepatide Programs as Thanksgiving Week Signals Start of Annual Weight Loss Planning ...